789 West Pender Street
Vancouver, BC V6C 1H2
Industry: Drug Manufacturers—Specialty & Generic
Full Time Employees:
|Mr. David Joshua Bartch||Co-Founder, CEO, Pres & Chairman||121.23k||N/A||1987|
|Mr. Robert Roscow||Co-Founder, Chief Scientific Officer & Director||137.99k||N/A||N/A|
|Mr. Damon Michaels||COO, Co-Founder & Director||159.31k||N/A||N/A|
|Mr. Dean Ditto||Chief Financial Officer||N/A||N/A||N/A|
|Mr. Sanford M. Stein||Gen. Counsel & Corp. Sec.||N/A||N/A||N/A|
|Mr. Jim Gunning||Chief Marketing Officer||N/A||N/A||N/A|
|Dr. Rakesh Jetly FRCPC, M.D.||Chief Medical Officer||N/A||N/A||N/A|
|Mr. Michel Rudolphie||Pres of the European Operations||N/A||N/A||N/A|
|Mr. William Cook||Interim CEO & Technical Director of Mindleap Health Inc.||N/A||N/A||N/A|
Mydecine Innovations Group Inc., a biotech and life sciences company, engages in the development and commercialization of drugs for treating mental health problems. It develops therapies for veterans, emergency medical service providers, post traumatic stress disorder, and frontline workers; and digital health solutions, such as digital therapeutics and quantified mental health solutions. The company also engages in the drug discovery and delivery activities. In addition, it is involved in the operation of real estate and farm properties in North America. Mydecine Innovations Group Inc. has a partnership with Applied Pharmaceutical Innovation for drug development and clinical trial programs. The company was formerly known as NewLeaf Brands Inc. and changed its name to Mydecine Innovations Group Inc. in June 2020. Mydecine Innovations Group Inc. is headquartered in Vancouver, Canada.
Mydecine Innovations Group Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.